Jake M. Bartholomew

TL;DR: It is found that higher neutralising antibody titres in patients aged 5 years and older with a diagnosis of IBD and being treated with infliximab or vedolizumab for 6 weeks or longer were associated with a lower hazard risk, compared with patients who had a breakthrough infection.

TL;DR: In this article , the authors address the work of Stefan Gandler, who has long advocated for the importance of Mexican philosophers and has also utilized their work to criticize the current iteration of Critical Theory in its second and third generations.

TL;DR: In this article , the authors report SARS-CoV-2 vaccine-induced immune responses and breakthrough infections in patients with inflammatory bowel disease, who are treated either with the anti-TNF antibody, infliximab, or with vedolizumab targeting a gut-specific anti-integrin that does not impair systemic immunity.